Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DM2DE9
|
|||
| Drug Name |
SB-728-mR-T
|
|||
| Drug Type |
Cell therapy
|
|||
| Indication | Human immunodeficiency virus-1 infection [ICD-11: 1C62; ICD-10: B20-B24; ICD-9: 42] | Phase 1/2 | [1] | |
| Company |
Sangamo Therapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02225665) A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.